Matinas BioPharma Holdings (MTNB) Accumulated Expenses (2013 - 2026)
Matinas BioPharma Holdings (MTNB) recorded Accumulated Expenses of $504,000 in Q2 2026, down 36.6% from $795,000 a year earlier and down 27.4% from the prior quarter.
Powered by 
Analysis
Matinas BioPharma Holdings (MTNB) Accumulated Expenses (2013 - 2026) Analysis & Trends
At the end of FY2025, Matinas BioPharma Holdings reported Accumulated Expenses of $452,000, down 75.0% from FY2024.
- Annual Accumulated Expenses has a five-year compound annual growth rate of -30.5% (FY2020 to FY2025).
- Across earlier years, Accumulated Expenses came in at $1.81 million in FY2024 (+24.7%), $1.45 million in FY2023 (-53.3%), $3.1 million in FY2022 (+8.7%) and $2.85 million in FY2021 (+2.0%).
- Quarterly Accumulated Expenses has ranged from $452,000 in Q4 2025 to $4.29 million in Q2 2022 over the past five years.
- On a year-over-year basis, Accumulated Expenses has declined for five consecutive quarters, with an average decline of 27.4% over the last eight quarters.
- Peak year-over-year performance for Accumulated Expenses in the last five years was growth of 55.4% in Q2 2022, against a decline of 75.0% in Q4 2025 at the low end.
- Per Business Quant, the preceding three quarters came in at $694,000 (Q1 2026), $452,000 (Q4 2025) and $564,000 (Q3 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Eli Lilly | 1,348.13 Bn | 1,321.74 Bn | 20.46 Bn |
| 2 | Johnson & Johnson | 675.90 Bn | 595.76 Bn | 17.30 Bn |
| 3 | AbbVie | 519.45 Bn | 487.50 Bn | 13.12 Bn |
| 4 | Merck | 364.95 Bn | 327.95 Bn | 13.19 Bn |
| 5 | Novartis Ag | 311.58 Bn | 285.16 Bn | - |
| 6 | Astrazeneca | 289.34 Bn | 262.94 Bn | 13.26 Bn |
| 7 | Amgen | 251.64 Bn | 203.30 Bn | 7.58 Bn |
| 8 | Gilead Sciences | 212.05 Bn | 187.07 Bn | 6.73 Bn |
| 9 | Pfizer | 167.35 Bn | 115.00 Bn | 12.56 Bn |
| 10 | Matinas BioPharma Holdings | 508,224.03 | -12.08 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 504,000.00 |
| Mar 31, 2026 | 694,000.00 |
| Dec 31, 2025 | 452,000.00 |
| Sep 30, 2025 | 564,000.00 |
| Jun 30, 2025 | 795,000.00 |
| Mar 31, 2025 | 1.18 Mn |
| Dec 31, 2024 | 1.81 Mn |
| Sep 30, 2024 | 1.04 Mn |
| Jun 30, 2024 | 1.44 Mn |
| Mar 31, 2024 | 839,000.00 |
| Dec 31, 2023 | 1.45 Mn |
| Sep 30, 2023 | 1.76 Mn |
| Jun 30, 2023 | 1.37 Mn |
| Mar 31, 2023 | 791,000.00 |
| Dec 31, 2022 | 3.10 Mn |
| Sep 30, 2022 | 3.70 Mn |
| Jun 30, 2022 | 4.29 Mn |
| Mar 31, 2022 | 1.84 Mn |
| Dec 31, 2021 | 2.85 Mn |
| Sep 30, 2021 | 2.89 Mn |
API Access
Matinas BioPharma Holdings Accumulated Expenses API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=accumulated-expenses&ticker=MTNB&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "accumulated-expenses", "ticker": "MTNB", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=accumulated-expenses&ticker=MTNB&period=max&api_key=YOUR_API_KEY");
const data = await res.json();